Daniel Lopez-Cruz

Chairman of the Board of Directors, InvestCorp

Daniel Lopez-Cruz

Education:
Daniel holds an MBA from the MIT Sloan School of Management and a dual degree in Law and Economics from ICADE. Daniel holds the FCA Senior Management Functions 1 (Chief Executive) & 3 (Executive Director).

Daniel Lopez-Cruz is the head of Investcorp’s European Private Equity group and a member of Investcorp’s global private equity investment committee. Since joining Investcorp in 2005, Daniel has been responsible for a number of private equity investments across a wide range of industries and European countries. He currently sits in the boards of Agromillora and SPG Prints and has previously served on the boards of Polyconcept, Icopal, Asiakastieto and Esmalglass.

Prior to Investcorp, Daniel was an Executive Director in Morgan Stanley’s investment banking group in New York and London and was previously a Director in UBS’s investment banking group in New York.

Celine Infeld

Board Member, InvestCorp

Celine Infeld

Education:
Celine holds an MBA from INSEAD and an MSc from the London School of Economics and NYU Stern School of Business.

Celine Infeld joined Investcorp in 2020. Prior to Investcorp Celine was the Group Managing Director of the Insight Group at Infopro Digital (formerly Incisive Media). During 12 years at Incisive Media, Celine held leadership positions in Sales, Strategy & M&A and Marketing, Product & Digital. Celine started her career at L.E.K. Consulting in both London and San Francesco.

Celine currently sits on the boards of Cambio Healthcare Systems, Georg Jensen and Sanos Group.

Sebastian Inger

Board Member, InvestCorp

Sebastian Inger

Education:
Sebastian has an International BSc and MSc in Finance with a sub-degree in Japanese, from the University of Gothenburg School of Business, Economics and Law in Sweden.

Sebastian Inger joined InvestCorp in 2013. Prior to InvestCorp he worked in the industrial team at Credit Suisse in London. Previously he worked at Swedbank in Sweden, in both the equity research team and corporate finance division.

Sebastian has been the Board Director for Sanos Group A/S since December 2020 and is also currently sitting on the boards of Cambio Healthcare Systems, Abax and Georg Jensen.

Jeppe Ragnar Andersen

Group CEO, Sanos Group

Jeppe Ragnar Andersen

Education:
Jeppe holds a MSc in Pharmacy from the University of Copenhagen and a MBA in International Business from the Quantic School of Business and Technology.

He joined Nordic Bioscience in 2007 and became Head of Clinical Development in 2010. Jeppe has been CEO of Nordic Bioscience Clinical Development A/S from 2014-2018 and is now CEO of Sanos Group which consists of NBCD A/S and Sanos A/S.

Jeppe is actively doing research into clinical trial methodology with a special focus on implementing risk-based monitoring and cost-benefit optimization. Over the years, Jeppe has been involved on an operational and executive level in numerous clinical studies with more than 15,000 patients within the therapeutic fields of osteoporosis, osteoarthritis and diabetes.

He has headed the successful merging of two clinical development departments and an expansion of the department with highly motivated employees from 3 employees to 30 employees.